Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market
VANI•Cash runway and market backdrop
Cash runway is expected to fund the current operating plan through 1H 2027, including completion of key milestones.
The deck cited $132 billion in 2025 global sales for FDA-approved GLP-1 products, with high discontinuation rates by year 1 and year 2.
NanoPortal GLP-1 implant strategy
Vivani outlined its NanoPortal ultra-long-acting subdermal GLP-1 implant platform targeting once- or twice-yearly dosing for chronic weight management.
Lead candidate NPM-139, a semaglutide implant, is in SLIM-1 with top-line data expected in Nov. 2026.
Phase 2 study design is underway with an anticipated 2027 start for NPM-139.
